Abstract
Jak2 is a nonreceptor tyrosine kinase that is essential for proper animal development and physiology. It is activated by ligand-occupied cell-surface receptors. Once activated, it then tyrosine phosphorylates the latent cytoplasmic transcription factors, termed the signal transducers and activators of transcription (STAT) proteins. Thus Jak2 is viewed as a classic mediator of ligand-dependent signal transduction. Recent studies, however, suggest that Jak2 may mediate cellular gene expression outside of the classically defined, ligand-activated, Jak/STAT-signaling paradigm. Here we review these studies, provide additional data, and discuss whether Jak2 is a mediator of ligand-independent gene transcription, and, in turn, whether our current understanding of the Jak/STAT signaling paradigm should be modified to incorporate these observations.
Similar content being viewed by others
References
Frank, S. J., Gilliland, G., Kraft, A. S., and Arnold, C. S. (1994) Interaction of the growth hormone receptor cytoplasmic domain with the JAK2 tyrosine kinase. Endocrinology 135, 2228–2239.
Ali, M. S., Sayeski, P. P., Dirksen, L. B., Hayzer, D. J., Marrero, M. B., and Bernstein, K. E. (1997) Dependence on the motif YIPP for the physical association of Jak2 kinase with the intracellular carboxyl tail of the angiotensin II AT1 receptor. J. Biol. Chem. 272, 23382–23388.
Sayeski, P. P., Ali, M. S., Frank, S. J., and Bernstein K. E. (2001) The angiotensin II-dependent nuclear translocation of Stat1 is mediated by the Jak2 protein motif 231YRFRR. J. Biol. Chem. 276, 10556–10563.
Witthuhn, B. A., Quelle, F. W., Silvennoinen, O., Yi, T., Tang, B., Miura, O., and Ihle J. N. (1993) JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythro-poietin. Cell 74, 227–236.
Argetsinger, L. S., Campbell, G. S., Yang, X., Witthuhn, B. A., Silvennoinen, O., Ihle, J. N., et al. (1993) Identification of JAK2 as a growth hormone receptor-associated tyrosine kinase. Cell 74, 237–244.
Rui, H., Kirken, R. A., and Farrar, W. L. (1994) Activation of receptor-associated tyrosine kinase JAK2 by prolactin. J. Biol. Chem. 269, 5364–5368.
Narazaki, M., Witthuhn, B. A., Yoshida, K., Silvennoinen, O., Yasukawa, K., Ihle, J. N., et al. (1994) Activation of JAK2 kinase mediated by the interleukin 6 signal transducer gp130. Proc. Natl. Acad. Sci. U S A 91, 2285–2289.
Marrero, M. B., Schieffer, B., Paxton, W. G., Heerdt, L., Berk, B. C., Delafontaine, P., et al. (1995) Direct stimulation of Jak/STAT pathway by the angiotensin II AT1 receptor. Nature 375, 247–250.
Saharinen, P., Takaluoma, K., and Silvennoinen, O. (2000) Regulation of the Jak2 tyrosine kinase by its pseudokinase domain. Mol. Cell. Biol. 20, 3387–3395.
Saharinen, P. and Silvennoinen, O. (2002) The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J. Biol. Chem. 277, 47954–47963.
Bernards, A. (1991) Predicted Tyk2 protein contains two tandem protein kinase domains. Oncogene 6, 1185–1187.
Harpur, A. G., Andres, A. C., Ziemiecki, A., Aston, R. R., and Wilks, A. F. (1992) JAK2, a third member of the JAK family of protein tyrosine kinases. Oncogene 7, 1347–1353.
Higgins, D. G., Thompson, J. D., and Gibson, T. J. (1996) Using CLUSTAL for multiple sequence alignments. Meth. Enzymol. 266, 383–402.
Kampa, D. and Burnside, J. (2000) Computational and functional analysis of the putative SH2 domain in Janus kinases. Biochem. Biophys. Res. Comm. 278, 175–182.
Giordanetto, F., and Kroemer, R. T. (2002) Prediction of the structure of human Janus kinase 2 (JAK2) comprising JAK homology domains 1 through 7. Protein Engineering 15, 727–737.
Girault, J. A., Labesse, G., Mornon, J., and Callebaut, I. (1998) Janus kinases and focal adhesion kinases play in the 4.1 band: a superfamily of band 4.1 domains important for cell structure and signal transduction. Mol. Med. 4, 751–769.
Yonemura, S., Hirao, M., Doi, Y., Takahashi, N., Kondo, T., Tsukita, S., et al. (1998) Ezrin/radixin/moesin (ERM) proteins bind to a positively charged amino acid cluster in the juxta-membrane cytoplasmic domain of CD44, CD43, and ICAM-2. J. Cell. Biol. 140, 885–895.
Tanner, J. W., Chen, W., Young, R. L., Longmore, G. D., and Shaw, A. S. (1995) The conserved box 1 motif of cytokine receptors is required for association with JAK kinases. J. Biol. Chem. 270, 6523–6530.
Zhao, Y. M., Wagner, F., Frank, S. J., and Kraft, A. S. (1995) The amino-terminal portion of the JAK2 protein kinase is necessary for binding and phosphorylation of the granulocyte macrophage colony-stimulating factor receptor beta c chain. J. Biol. Chem. 270, 13814–13818.
Schindler, C., Shuai, K., Prezioso, V. R., and Darnell, J. E., Jr. (1992) Interferon-dependent tyrosine phosphorylation of a latent cytoplasmic transcription factor. Science 257, 809–813.
Ju, H., Venema, V. J., Liang, H., Harris, M. B., Zou, R., and Venema, R. C. (2000) Bradykinin activates the Janus-activated kinase/signal transducers and activators of transcription (JAK/STAT) pathway in vascular endothelial cells: localization of JAK/STAT signaling proteins in plasmalemmal caveolae. Biochem. J. 351, 257–264.
Peeler, T. C., Conrad, K. M., and Baker, K. M. (1996) Endothelin stimulates sis-inducing factor-like DNA binding activity in CHO-K1 cells expressing ETa receptors. Biochem. Biophys. Res. Comm. 221, 62–66.
Lukashova, V., Chen, Z., Duhe, R. J., Rola-Pleszczynski, M., and Stankova, J. (2003) Janus kinase 2 activation by the platelet-activating factor receptor (PAFR): roles of Tyk2 and PAFR C terminus. J. Immunol. 171, 3794–3800.
Buggy, J. J. (1998) Binding of α-melanocyte-stimulating hormone to its G protein-coupled receptor on B-lymphocytes activates the Jak/Stat pathway. Biochem. J. 331, 211–216.
Sasaguri, T., Teruya, H., Ishida, A., Abumiya, T., and Ogata, J. (2000) Linkage between α1 adrenergic receptor and the Jak/Stat signaling pathway in vascular smooth muscle cells. Biochem. Biophys. Res. Comm. 268, 25–30.
Meuller, A. and Strange, P. G. (2004) CCL3, acting via the chemokine receptor CCR5, leads to independent activation of Janus kinase 2 (Jak2) and Gi proteins. FEBS Lett. 570, 126–132.
Huang, L. J., Constantinescu, S. N., and Lodish, H. F. (2001) The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor. Mol. Cell 8, 1327–1338.
Harrison, D. A., Binari, R., Nahreini, T. S., Gilman, M., and Perrimon, N. (1995) Activation of a Drosophila Janus kinase (JAK) causes hematopoietic neoplasia and developmental defects. EMBO J. 14, 2857–2865.
Luo, H., Rose, P., Barber, D., Hanratty, W. P., Lee, S., Roberts, T. M. et al. (1997) Mutation in the Jak kinase JH2 domain hyperactivates Drosophila and mammalian Jak-Stat pathways. Mol. Cell. Biol. 17, 1562–1571.
Lacronique, V., Boureux, A., Valle, V. D., Poirel, H., Quang, C. T., Mauchauffe, M., et al. (1997) A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 278, 1309–1312.
Peeters, P., Raynaud, S. D., Cools, J., Wlodarska, I., Grosgeorge, J., Philip, P., et al. (1997) Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 90, 2535–2540.
Ho, J. M., Beattie, B. K., Squire, J. A., Frank, D. A., and Barber, D. L. (1999) Fusion of the ets transcription factor TEL to Jak2 results in constitutive Jak-Stat signaling. Blood 93, 4354–4364.
Lacronique, V., Boureux, A., Monni, R., Dumon, S., Mauchauffe, M., Mayeux, P., et al. (2000) Transforming properties of chimeric TEL-JAK proteins in BA/F3 cells. Blood 95, 2076–2083.
Carron, C., Cormier, F., Janin, A., Lacronique, V., Giovannini, M., Daniel, M. T., et al. (2000) TEL-JAK2 transgenic mice develop T-cell leukemia. Blood 95, 3891–3899.
Feng, J., Witthuhn, B. A., Matsuda, T., Kohlhuber, F., Kerr, I. M., and Ihle, J. N. (1997) Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop. Mol. Cell. Biol. 17, 2497–2501.
Feener, E. P., Rosario, F., Dunn, S. L., Stancheva, Z., and Myers, M. G. Jr. (2004) Tyrosine phosphorylation of Jak2 in the JH2 domain inhibits cytokine signaling. Mol. Cell. Biol. 11, 4968–4978.
Argetsinger, L. S., Kouadio, J. L., Steen, H., Stensballe, A., Jensen, O. N., and Carter-Su, C. (2004) Autophosphorylation of JAK2 on tyrosines 221 and 570 regulates its activity. Mol. Cell. Biol. 11, 4955–4967.
Kurzer, J. H., Argetsinger, L. S., Zhou, Y. J., Kouadio, J. L., O'Shea, J. J., and Carter-Su, C. (2004) Tyrosine 813 is a site of JAK2 autophosphorylation critical for activation of JAK2 by SH2-B beta. Mol. Cell. Biol. 10, 4557–4570.
Rui, L., Mathews, L. S., Hotta, K., Gustafson, T. A., and Carter-Su, C. (1997) Identification of SH2-Bb as a substrate of the tyrosine kinase JAK2 involved in growth hormone signaling. Mol. Cell. Biol. 17, 6633–6644.
Yin, T., Shen, R., Feng, G. S., and Yang, Y. C. (1997) Molecular characterization of specific interactions between SHP-2 phosphatase and JAK tyrosine kinases. J. Biol. Chem. 272, 1032–1037.
Chatti, K., Farrar, W. L., and Duhe, R. J. (2004) Tyrosine phosphorylation of the Janus kinase 2 activation loop is essential for a high-activity catalytic state but dispensable for a basal catalytic state. Biochemistry 43, 4272–4283.
Wallace, T. W., VonDerLinden, D., He, K., Frank, S. J., and Sayeski, P. P. (2004) Microarray analyses identify JAK2 tyrosine kinase as a key mediator of ligand-independent gene expression. Am. J. Physiol. Cell Physiol. 287, C981-C991.
Kohlhuber, F., Rogers, N. C., Watling, D., Feng, J., Guschin, D., Briscoe, J., et al. (1997) A JAK1/JAK2 chimera can sustain alpha and gamma interferon responses. Mol. Cell. Biol. 17, 695–706.
Sayeski, P. P., Ali, M. S., Safavi, A., Lyles, M., Kim, S. O., Frank, S. J., et al. (1999) A catalytically active Jak2 is required for the angiotensin II-dependent activation of Fyn. J. Biol. Chem. 274, 33131–33142.
Hafner, C., Schmitz, G., Meyer, S., Bataille, F., Hau, P., Langmann, T., et al. (2004) Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers. Clin. Chem. 50, 490–499.
Tang, X. X., Evans, A. E., Zhao, H., Cnaan, A., London, W., Cohn, S. L., et al. (1999) High-level expression of EphB6, EFNB2, and EFNB3 is associated with low tumor stage and high TrkA expression in human neuroblastomas. Clin. Cancer Res. 35, 1491–1496.
Fox, B. P. and Kandpal, R. P. (2004) Invasiveness of breast carcinoma cells and transcript profile: Eph receptors and ephrin ligands as molecular markers of potential diagnostic and prognostic application. Biochem. Biophys. Res. Commun. 318, 882–892.
He, K., Wang, X., Jiang, J., Guan, R., Bernstein, K. E., Sayeski, P. P., et al. (2003) JAK2 determinants for GH receptor association, surface assembly, and signaling. Mol. Endocrinol. 17, 2211–2227.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wallace, T.A., Sayeski, P.P. Jak2 tyrosine kinase. Cell Biochem Biophys 44, 213–222 (2006). https://doi.org/10.1385/CBB:44:2:213
Issue Date:
DOI: https://doi.org/10.1385/CBB:44:2:213